A dose of 360 mg/kg/day was associated with increased mortality in treated males and females and a reduced fertility index. Throughout chronic dosing, rebound was not observed in any isosorbide mononitrate extended-release tablet treatment group.
When methemoglobinemia is diagnosed, the treatment of choice is methylene blue, 1-2 mg/kg intravenously.The recommended regimen of Isosorbide Mononitrate Tablets is 20 mg twice daily, with the doses seven hours apart.
Ask your doctor before using any headache pain medication.Common isosorbide mononitrate side effects may include:This is not a complete list of side effects and others may occur.
... CAS number and/or the molecular and structural formulas.
• isosorbide-5-mononitrate Each ISMO Retard prolonged-release tablet contains 40 mg of isosorbide-5-mononitrate. The empirical formula is C Uses.
Substances listed in the EINECS, ELINCS, or NLP inventories. This Directive establishes rules for the safe transport of dangerous goods between EU countries by road, rail, and waterway. (See table at end of Aspirin and/or acetaminophen, on the other hand, often successfully relieve isosorbide mononitrate-induced headaches with no deleterious effect on isosorbide mononitrate's antianginal efficacy.Treatment with isosorbide mononitrate may be associated with light-headedness on standing, especially just after rising from a recumbent or seated position.
ADR Dangerous Goods Lists, Directive 2008/68/EC, EU.
Only 2% of the dose was excreted as unchanged drug.The overall elimination half-life of isosorbide mononitrate is about 5 hours. This medication belongs to a class of drugs known as nitrates. These hemodynamic changes may have protean manifestations, including increased intracranial pressure, with any or all of persistent throbbing headache, confusion, and moderate fever; vertigo; palpitations; visual disturbances; nausea and vomiting (possibly with colic and even bloody diarrhea); syncope (especially in the upright posture); air hunger and dyspnea, later followed by reduced ventilatory effort; diaphoresis, with the skin either flushed or cold and clammy; heart block and bradycardia; paralysis; coma; seizures and death.Laboratory determinations of serum levels of isosorbide mononitrate and its metabolites are not widely available, and such determinations have, in any event, no established role in the management of isosorbide mononitrate overdose.There are no data suggesting what dose of isosorbide mononitrate is likely to be life-threatening in humans.
Do not take this medicine in larger or smaller amounts or for longer than recommended. In the only regimen of twice-daily isosorbide mononitrate that has been shown to avoid development of tolerance, the two doses of Isosorbide Mononitrate Tablets are given 7 hours apart, so there is a gap of 17 hours between the second dose of each day and the first dose of the next day. In that case, the ATP (Adaptation to Technical Progress) number is displayed.If available, additional information on classification and labelling (C&L) is derived from If no EU harmonised classification and labelling exists and the substance was not registered under REACH, information derived from classification and labelling (C&L) notifications to ECHA under CLP Regulation is displayed under this section.
They are supplied as follows:Store at 20° - 30°C (68° - 86°F) [See USP]. Ask your pharmacist if you have any questions about the new brand of medicine you receive at the pharmacy.Use this medicine regularly to prevent an angina attack. The other ingredients are lactose monohydrate, microcrystalline cellulose (PH 102) (E460), sodium starch glycolate (type A), colloidal anhydrous silicon dioxide (E551) and magnesium stearate (E470b). Substances indicated, in 2009, as being intended to be registered by at least one company in the EEA.
When methemoglobinemia is diagnosed, the treatment of choice is methylene blue, 1-2 mg/kg intravenously.The recommended regimen of Isosorbide Mononitrate Tablets is 20 mg twice daily, with the doses seven hours apart.
Ask your doctor before using any headache pain medication.Common isosorbide mononitrate side effects may include:This is not a complete list of side effects and others may occur.
... CAS number and/or the molecular and structural formulas.
• isosorbide-5-mononitrate Each ISMO Retard prolonged-release tablet contains 40 mg of isosorbide-5-mononitrate. The empirical formula is C Uses.
Substances listed in the EINECS, ELINCS, or NLP inventories. This Directive establishes rules for the safe transport of dangerous goods between EU countries by road, rail, and waterway. (See table at end of Aspirin and/or acetaminophen, on the other hand, often successfully relieve isosorbide mononitrate-induced headaches with no deleterious effect on isosorbide mononitrate's antianginal efficacy.Treatment with isosorbide mononitrate may be associated with light-headedness on standing, especially just after rising from a recumbent or seated position.
ADR Dangerous Goods Lists, Directive 2008/68/EC, EU.
Only 2% of the dose was excreted as unchanged drug.The overall elimination half-life of isosorbide mononitrate is about 5 hours. This medication belongs to a class of drugs known as nitrates. These hemodynamic changes may have protean manifestations, including increased intracranial pressure, with any or all of persistent throbbing headache, confusion, and moderate fever; vertigo; palpitations; visual disturbances; nausea and vomiting (possibly with colic and even bloody diarrhea); syncope (especially in the upright posture); air hunger and dyspnea, later followed by reduced ventilatory effort; diaphoresis, with the skin either flushed or cold and clammy; heart block and bradycardia; paralysis; coma; seizures and death.Laboratory determinations of serum levels of isosorbide mononitrate and its metabolites are not widely available, and such determinations have, in any event, no established role in the management of isosorbide mononitrate overdose.There are no data suggesting what dose of isosorbide mononitrate is likely to be life-threatening in humans.
Do not take this medicine in larger or smaller amounts or for longer than recommended. In the only regimen of twice-daily isosorbide mononitrate that has been shown to avoid development of tolerance, the two doses of Isosorbide Mononitrate Tablets are given 7 hours apart, so there is a gap of 17 hours between the second dose of each day and the first dose of the next day. In that case, the ATP (Adaptation to Technical Progress) number is displayed.If available, additional information on classification and labelling (C&L) is derived from If no EU harmonised classification and labelling exists and the substance was not registered under REACH, information derived from classification and labelling (C&L) notifications to ECHA under CLP Regulation is displayed under this section.
They are supplied as follows:Store at 20° - 30°C (68° - 86°F) [See USP]. Ask your pharmacist if you have any questions about the new brand of medicine you receive at the pharmacy.Use this medicine regularly to prevent an angina attack. The other ingredients are lactose monohydrate, microcrystalline cellulose (PH 102) (E460), sodium starch glycolate (type A), colloidal anhydrous silicon dioxide (E551) and magnesium stearate (E470b). Substances indicated, in 2009, as being intended to be registered by at least one company in the EEA.